Patent intelligence · NO
NO 2026007
Serplulimab
Serplulimab
Patent details — NO 2026007
- Jurisdiction
- NO
- Status
- granted
- Grant date
- Jan 22, 2026
- Expiration
- Jan 17, 2046
- Applicant
- ACCORD HEALTHCARE S L U [ES]
- CPC classes
- A61K 39/ 395 A I, A61K 47/ 68 A I, A61K 49/ 16 A I, A61K 51/ 10 A I
Quick answer
NO 2026007 (Serplulimab) is held by ACCORD HEALTHCARE S L U [ES]. Status: granted. Granted Jan 22, 2026. Expires Jan 17, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACCORD HEALTHCARE S L U [ES]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 395 A I, A61K 47/ 68 A I, A61K 49/ 16 A I, A61K 51/ 10 A I, A61K/39395, A61K/476849
Related coverage
Frequently asked questions
What is US patent 2026007?
NO 2026007 (Serplulimab) is held by ACCORD HEALTHCARE S L U [ES]. Status: granted. Granted Jan 22, 2026. Expires Jan 17, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns NO 2026007?
ACCORD HEALTHCARE S L U [ES] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does NO 2026007 expire?
Our index shows an expiration date of Jan 17, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.